The European approach to in-transit melanoma lesions

References

• de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355–2366
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. Clin Oncol 2005; 23: 4588–4590
   Google Scholar
• Schraffordt Koops H, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906–2912
   PubMedGoogle Scholar
• http://www.cancerstaging.org/cstage/manuals.html. Accessed 30 August 2007.
   Google Scholar
• Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: Implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14: 1924–1933
   PubMed Web of Science ®Google Scholar
• Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: Long-term results of the multi-institutional randomized surgical trial. Ann Surg Oncol 1996; 3: 446–452
   PubMed Web of Science ®Google Scholar
• Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable?. Ann Surg Oncol 1999; 6: 315–321
   PubMed Web of Science ®Google Scholar
• Francken AB, Bastiaannet E, Hoekstra HJ. Follow–up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6: 608–621
   PubMed Web of Science ®Google Scholar
• Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in–transit recurrent melanoma?. Ann Surg 2003; 238: 743–747
   PubMed Web of Science ®Google Scholar
• Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006; 93: 243–249
   PubMed Web of Science ®Google Scholar
• van Leeuwen BL, Houwerzijl M, Hoekstra HJ. Educational tips in the treatment of malignant ulcerating tumours of the skin. Eur J Surg Oncol 2000; 26: 506–508
   PubMedGoogle Scholar
• Karakousis CP, Choe KJ, Holyoke ED. Biologic behavior and treatment of intransit metastasis of melanoma. Surg Gynecol Obstet 1980; 150: 29–32
   PubMedGoogle Scholar
• Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989; 169: 1–6
   PubMedGoogle Scholar
• Gibson SC, Byrne DS, McKay AJ. Ten–year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg 2004; 91: 893–895
   PubMed Web of Science ®Google Scholar
• Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette–Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993; 19: 985–990
   PubMedGoogle Scholar
• Strobbe LJ, Hart AA, Rümke P, Israels SP, Nieweg OE, Kroon BB. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997; 7: 507–512
   PubMed Web of Science ®Google Scholar
• Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T, McCarthy WH. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005; 15: 45–51
   PubMed Web of Science ®Google Scholar
• Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10: 115–121
   PubMed Web of Science ®Google Scholar
• Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3–20
   PubMed Web of Science ®Google Scholar
• Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616–632
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20: 1351–1381
   PubMed Web of Science ®Google Scholar
• Fontijne WP, Mook PH, Schraffordt Koops H, Oldhoff J, Wildevuur CR. Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study. Cancer 1985; 55: 1455–1461
   Google Scholar
• Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis H. Isolated regional perfusion in malignant melanoma of the extremities. World J Surg 1987; 11: 527–533
   PubMed Web of Science ®Google Scholar
• Daryanani D, Komdeur R, Ter Veen J, Nijhuis PH, Piers DA, Hoekstra HJ. Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 2001; 8: 566–572
   PubMed Web of Science ®Google Scholar
• Guchelaar HJ, Hoekstra HJ, de Vries EGE, Uges DR, Oosterhuis JW, Schraffordt Koops H. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer 1992; 65: 898–902
   PubMed Web of Science ®Google Scholar
• Zwaveling JH, Maring JK, Clarke FL, van Ginkel RJ, Limburg PC, Hoekstra HJ, Schraffordt Koops H, Girbes AR. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med 1996; 24: 765–770
   PubMed Web of Science ®Google Scholar
• Schraffordt Koops H. Prevention of neural and muscular lesions during hyperthermic regional perfusion. Surg Gynecol Obstet 1972; 135: 528–531
   Google Scholar
• Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905–910
   PubMedGoogle Scholar
• Baas PC, Hoekstra HJ, Schraffordt Koops H, Ooosterhuis JW, van der Weele LTH, et al. Results of hyperthermic isolated regional perfusion of locally metastasized melanoma of the lower extremity with melphalan with or without dactinamycin using different dosage methods. Regional Cancer Treatment 1989; 2: 87–91
   Google Scholar
• Hoekstra HJ, Schraffordt Koops H, de Vries EGE, van Weerden TW, Oldhoff J. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993; 72: 1224–1229
   PubMed Web of Science ®Google Scholar
• Daryanani D, de Vries EGE, Guchelaar HJ, van Weerden TW, Hoekstra HJ. Hyperthermic isolated regional perfusion of the limb with carboplatin. Eur J Surg Oncol 2000; 26: 792–797
   PubMed Web of Science ®Google Scholar
• de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000–1003
   PubMed Web of Science ®Google Scholar
• Franklin HR, Schraffordt Koops H, Oldhoff J, Czarnetzki BM, Macher E, Kroon BB, et al. To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 1988; 6: 701–708
   PubMed Web of Science ®Google Scholar
• Ghussen F, Kruger I, Groth W, Stutzer H. The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988; 61: 654–659
   PubMed Web of Science ®Google Scholar
• Hafström L, Rudenstam CM, Blomquist E, Ingvar C, Jönsson PE, Lagerlöf B, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9: 2091–2094
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, Hart AA. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115: 39–45
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, van Dongen JA. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71: 2990–2994
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903–907
   PubMed Web of Science ®Google Scholar
• Lienard D, Eggermont AM, Schraffordt Koops H, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res 1999; 9: 491–502
   PubMed Web of Science ®Google Scholar
• Fraker DL, Alexander H, Ross M, et al. A trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. Ann Surg Oncol 2002; 9(suppl.)S8
   Google Scholar
• Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004; 139: 1237–1242
   PubMedGoogle Scholar
• Grunhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004; 240: 939–947
   PubMed Web of Science ®Google Scholar
• Rossi CR, Foletto M, Mocellin S, Pilati P, Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004; 11: 173–177
   PubMed Web of Science ®Google Scholar
• Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: ACOSOG Trial Z0020. J Clin Oncol 2006; 24: 4196–4201
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Eggermont AM. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 2007; 25: 1449–1450
   PubMed Web of Science ®Google Scholar
• Rüegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408–414
   PubMed Web of Science ®Google Scholar
• van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397–408
   PubMed Web of Science ®Google Scholar
• Rossi CR, Russano F, Mocellin S, Chiarion-Sileni V, Foletto M, Pilati P, et al. TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases. A pilot. Oral presentation Society of Surgical Oncology 2007
   Google Scholar
• Feldman AL, Alexander HR, Jr, Bartlett DL, Fraker DL, Libutti SK. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999; 6: 562–567
   PubMed Web of Science ®Google Scholar
• Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997; 80: 2084–2090
   PubMed Web of Science ®Google Scholar
• Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005; 12: 609–615
   PubMed Web of Science ®Google Scholar
• Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 2006; 32: 318–324
   PubMed Web of Science ®Google Scholar
• Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002; 9: 968–974
   PubMed Web of Science ®Google Scholar
• Baas PC, Schraffordt Koops H, Hoekstra HJ, Oosterhuis JW, van der Weele LTh, et al. Isolated regional perfusion in the treatment of local recurrence, satellitosis and intransit metastases of melanomas of the extremities. Reg Cancer Treat 1988; 1: 33–36
   Google Scholar
• Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Reg Cancer Treat 1994; 7: 188–192
   Google Scholar
• Lindner P, Doubrovsky A, Kam PCA, Thompson JF. Prognostic factors after isolated limb infusion with cytostatic agents for melanoma. Ann Surg Oncol 2002; 9: 127–136
   PubMed Web of Science ®Google Scholar
• Lindner P, Thompson JF, De Wilt JH, Colman M, Kam PC. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 2004; 30: 433–439
   PubMed Web of Science ®Google Scholar
• Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; 1: CD005413
   Google Scholar